Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model

18 Mar 2010

Abstract excerpt

Aims To explore the cost-effectiveness of alternative methods of screening family members for hypertrophic cardiomyopathy (HCM), the most common monogenic cardiac disorder and the most frequent cause of sudden cardiac death (SCD) in young people. Methods and results Economic decision model comparing cascade screening by genetic, as opposed to clinical methods. The incremental cost per life year saved was 14,397...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiac pacing and defibrillation studies
Share to Cardiomyopathy and Myosin Studies
Share to Cardiovascular Effects of Exercise

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20299350
DOI: 10.1093/eurheartj/ehq067

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness modelPMID 20299350Read ↗

A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathySemantic proximity Read ↗

Cascade health service use in family members following genetic testing in children: a scoping literature reviewSemantic proximity Read ↗

Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies.Semantic proximity Read ↗

A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy.Semantic proximity Read ↗

Cost-effectiveness of cascade genetic testing for familial hypercholesterolemia in the United States: A simulation analysisSemantic proximity Read ↗

An evaluation of the cost-effectiveness of population genetic screening for familial hypercholesterolemia in US patients.Semantic proximity Read ↗

A Systematic Review on the Cost-Effectiveness of Genetic and Electrocardiogram Testing for Long QT Syndrome in Infants and Young Adults.Semantic proximity Read ↗

Uptake of Cardiac Screening and Genetic Testing Among Hypertrophic and Dilated Cardiomyopathy FamiliesSemantic proximity Read ↗

Cardiomyopathy genetic testing: insights into demographics, counseling, and cascade screening.Semantic proximity Read ↗

Cost-effectiveness of alternative cascade screening strategies for familial hypercholesterolemia with realistic cascade screening acceptance rates and use of novel treatment.Semantic proximity Read ↗

Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers.Semantic proximity Read ↗

Yield of molecular and clinical testing for arrhythmia syndromes: report of 15 years' experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.